modified to include one or more limitations found in any other claim that is dependent on the same base claim.

Where elements are presented as lists, *e.g.*, in Markush group format, it is to be understood that each subgroup of the elements is also disclosed, and any element(s) can be removed from the group. It should it be understood that, in general, where the invention, or aspects of the invention, is/are referred to as comprising particular elements, features, etc., certain embodiments of the invention or aspects of the invention consist, or consist essentially of, such elements, features, etc. For purposes of simplicity those embodiments have not been specifically set forth *in haec verba* herein. It is also noted that the term "comprising" is intended to be open and permits the inclusion of additional elements or steps.

Where ranges are given, endpoints are included. Furthermore, it is to be understood that unless otherwise indicated or otherwise evident from the context and understanding of one of ordinary skill in the art, values that are expressed as ranges can assume any specific value or sub-range within the stated ranges in different embodiments of the invention, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise.

The term "about" or "approximately" can mean within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, e.g., the limitations of the measurement system. For example, "about" can mean within 1 or more than 1 standard deviations, per the practice in the art. Alternatively, "about" can mean a range of up to 20%, up to 10%, up to 5%, or up to 1% of a given value. Alternatively, the term can mean within an order of magnitude, for example, within 5-fold, or within 2-fold, of a value. Where particular values are described in the application and claims, unless otherwise stated the term "about" meaning within an acceptable error range for the particular value should be assumed.

In addition, it is to be understood that any particular embodiment of the present invention that falls within the prior art may be explicitly excluded from any one or more of the claims. Since such embodiments are deemed to be known to one of ordinary skill in the art, they may be excluded even if the exclusion is not set forth explicitly herein. Any particular embodiment of the methods of the invention can be excluded from any one or more claims, for any reason, whether or not related to the existence of prior art.

~~What is claimed is:~~

CLAIMS

1. A composition, comprising:

an isolated polypeptide that is an extracellular ligand-binding portion of a human p75 tumor necrosis factor receptor fused to the Fc region of a human IgG1; and

salt in an amount sufficient to prevent aggregation of the isolated polypeptide, thereby stabilizing the composition,

wherein the composition comprises L-arginine at a concentration of less than 1 mM.~~,~~

~~2. The composition of claim 1, wherein the composition comprises L-arginine at a concentration of less than 0.1 mM.~~

~~3. The composition of claim 2, wherein the composition comprises L-arginine at a concentration of less than 0.01 mM.~~

~~4. The composition of claim 3, wherein the composition comprises L-arginine at a concentration of less than 0.001 mM.~~

~~5. The composition of claim 4, wherein the composition is free of L-arginine.~~

~~6. The composition of any of claims 1-5, comprising about 10 mg/ml to about 100 mg/ml of the isolated polypeptide.~~

~~7. The composition of any of claims 1-6, wherein the isolated polypeptide is etanercept.~~

~~8. The composition of claim 1,wherein the composition further comprises aqueous buffer.~~

~~9. The composition of claim 8, wherein the aqueous buffer is sodium phosphate, histidine, potassium phosphate, sodium or potassium citrate, maleic acid, ammonium acetate, tris-(hydroxymethyl)-aminomethane (tris), acetate, diethanolamine or a combination thereof.~~

~~10. The composition of claim 8 or 9, wherein the aqueous buffer is present at a concentration of about 1 mM to about 15 mM.~~

~~11. The composition of any of claims 1-10, wherein the salt is sodium chloride.~~

~~12. The composition of any of claims 1-11, wherein the salt is present at a concentration of about 120 mM to about 150 mM.~~

~~13. The composition of any of claims 1-12, further comprising an excipient.~~

~~14. The composition of any of claims 1-13, wherein the excipient is sucrose, lactose, glycerol, xylitol, sorbitol, Mannitol, maltose, inositol, trehalose, glucose, bovine serum albumin (BSA), human SA or recombinant HA, dextran, PVA, hydroxypropyl methylcellulose (HPMC), polyethyleneimine, gelatin, polyvinylpyrrolidone (PVP), hydroxyethylcellulose (HEC), polyethylene glycol, ethylene glycol, glycerol, dimethysulfoxide (DMSO), dimethylformamide (DMF), proline, L-serine, sodium glutamic acid, alanine, glycine, lysine hydrochloride, sarcosine, gamma-aminobutyric acid, Tween-20, Tween-80, SDS, polysorbate, polyoxyethylene copolymer, potassium phosphate, sodium acetate, ammonium sulfate, magnesium sulfate, sodium sulfate, trimethylamine N-oxide, betaine, zinc ions, copper ions, calcium ions, manganese ions, magnesium ions, CHAPS, sucrose monolaurate, 2-O-beta-mannoglycerate or a combination thereof.~~

~~15. The composition of any of claims 1-14, wherein the excipient is sucrose.~~

~~16. The composition of any of claims 1-15, wherein the excipient is sucrose at a concentration of from about 0.5% to about 1.5%.~~

~~17. The composition of any of claims 1-16, wherein the pH of the composition is about 5.5 to about 7.8.~~

~~18. T~~ wherein the composition ~~of claim 1~~ does not contain added free amino acids, wherein said composition~~,~~ comprises~~ing~~ 50 mg/ml etanercept, about 10 mM sodium

phosphate, about 140 mM sodium chloride, ~~and~~ about 1% sucrose, and wherein the pH of the composition is about pH 6.0 to about pH 7.0.

~~19. The composition of any of claims 1-18, wherein the composition has a commercially viable shelf life of at least 24 months.~~

~~20. The composition of any of claims 1-19, wherein the composition is suitable for subcutaneous administration.~~

~~21. The composition of any of claims 1-20, wherein the isolated polypeptide is purified.~~

~~22. The composition of any of claims 1-21, wherein the composition is sterilized.~~

~~23~~. A composition, comprising:

an isolated polypeptide that is an extracellular ligand-binding portion of a human p75 tumor necrosis factor receptor fused to the Fc region of a human IgG1;

aqueous buffer at a concentration of less than 25 mM; and

salt at a concentration of greater than 100 mM,

wherein the composition comprises L-arginine at a concentration of less than 1 mM, and wherein the composition does not contain added free amino acids.

~~24~~3. The composition of claim ~~23~~, wherein the composition comprises L-arginine at a concentration of less than 0.1 mM.

~~25~~4. The composition of claim ~~24~~ 3, wherein the composition comprises L-arginine at a concentration of less than 0.01 mM.

~~26~~5. The composition of claim ~~25~~ 4, wherein the composition comprises L-arginine at a concentration of less than 0.001 mM.

~~27~~6. The composition of claim ~~26~~ 5, wherein the composition is free of L-arginine.

~~28~~7. A composition, consisting essentially of:

an isolated polypeptide that is an extracellular ligand-binding portion of a human p75 tumor necrosis factor receptor fused to the Fc region of a human IgG1;

aqueous buffer at a concentration of about 10 mM;

salt at a concentration of about 140 mM; and

sucrose, and wherein the composition does not contain added free amino acids.

~~29~~8. The composition of claim ~~28~~ 7, wherein the isolated polypeptide is present at a concentration of 50 mg/mL.

~~30~~9. The composition of claim ~~28~~7 or ~~29~~claim 8, wherein the polypeptide is etanercept.

10. The composition according to any one of claims 1 to 9, for use in treating an individual.

11. Use of the composition according to any one of claims 1 to 9 in the preparation of a medicament for the treatment of an individual diagnosed with a disease or disorder selected from rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Wegener's disease (granulomatosis), Crohn's disease (or inflammatory bowel disease), chronic obstructive pulmonary disease (COPD), Hepatitis C, endometriosis, asthma, cachexia, psoriasis or atopic dermatitis.

~~31. A method, comprising administering to an individual a composition, comprising:~~

~~an isolated polypeptide that is an extracellular ligand-binding portion of a human p75 tumor necrosis factor receptor fused to the Fc region of a human IgG1;~~

~~aqueous buffer; and~~

~~salt in an amount sufficient to prevent aggregation of the polypeptide, thereby stabilizing the composition,~~

~~wherein the composition comprises L-arginine at a concentration of less than 1 mM.~~

~~32. The method of claim 31, wherein the composition comprises L-arginine at a concentration of less than 0.1 mM.~~

~~33. The method of claim 32, wherein the composition comprises L-arginine at a concentration of less than 0.01 mM.~~

~~34. The method of claim 33, wherein the composition comprises L-arginine at a concentration of less than 0.001 mM.~~

~~35. The method of claim 34, wherein the composition is free of L-arginine.~~

~~36. The method of any of claims 31-35, wherein the composition comprises about 10 mg/ml to about 100 mg/ml of the isolated polypeptide.~~

~~37. The method of any one of claims 31-36, wherein the polypeptide is etanercept.~~

~~38. The method of any of claims 31-37, wherein the aqueous buffer is sodium phosphate, histidine, potassium phosphate, sodium or potassium citrate, maleic acid, ammonium acetate, tris-(hydroxymethyl)-aminomethane (tris), acetate, diethanolamine or a combination thereof.~~

~~39. The method of any of claims 31-38, wherein the aqueous buffer is present at a concentration of about 1 mM to about 15 mM.~~

~~40. The method of any of claims 31-39, wherein the salt is sodium chloride.~~

~~41. The method of any of claims 31-40, wherein the salt is present at a concentration of about 120 mM to about 150 mM.~~

~~42. The method of any of claims 31-41, wherein the composition further comprises comprising an excipient.~~

~~43. The method of 42, wherein the excipient is sucrose, lactose, glycerol, xylitol, sorbitol, Mannitol, maltose, inositol, trehalose, glucose, bovine serum albumin (BSC), human SC or recombinant HC, dextran, PVC, hydroxypropyl methylcellulose (HPMC), polyethyleneimine, gelatin, polyvinylpyrrolidone (PVP), hydroxyethylcellulose (HEC), polyethylene glycol, ethylene glycol, glycerol, dimethysulfoxide (DMSO), dimethylformamide (DMF), proline, L-~~

~~serine, sodium glutamic acid, alanine, glycine, lysine hydrochloride, sarcosine, gamma-aminobutyric acid, Tween 20, Tween 80, SDS, polysorbate, polyoxyethylene copolymer, potassium phosphate, sodium acetate, ammonium sulfate, magnesium sulfate, sodium sulfate, trimethylamine N-oxide, betaine, zinc ions, copper ions, calcium ions, manganese ions, magnesium ions, CHCPS, sucrose monolaurate, 2-O beta-mannoglycerate or a combination thereof.~~

~~44. The method of claim 42 or 43, wherein the excipient is sucrose.~~

~~45. The method of claim 44, wherein the excipient is sucrose at a concentration of from about 0.5% to about 1.5%.~~

~~46. The method of any of claims 31-45, wherein the pH of the composition is about 5.5 to about 7.8.~~

~~47. The method of claim 31, wherein the composition comprises 50 mg/ml etanercept, about 10 mM sodium phosphate, about 140 mM sodium chloride, and about 1% sucrose, wherein the pH of the method is about pH 6.0 to about pH 7.0.~~

~~48. The method of any of claims 31-47, wherein the composition has a commercially-viable shelf life of at least 24 months.~~

~~49. The method of any of claims 31-48, wherein the composition is suitable for subcutaneous administration.~~

~~50. The method of any of claims 31-49, wherein the isolated polypeptide is purified.~~

~~51. The method of any of claims 31-50, wherein the composition is sterilized.~~

~~52. The method of any of claims 31-51, wherein the individual is diagnosed with a disease or disorder selected from rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Wegener's disease (granulomatosis), Crohn's disease (or inflammatory bowel disease), chronic obstructive pulmonary disease (COPD), Hepatitis C, endometriosis, asthma, cachexia, psoriasis,~~

~~or atopic dermatitis.~~

~~53. The method of claim 52, wherein the composition is administered to the individual in an amount sufficient to treat the disease or disorder.~~